Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 9, 2007

Genedata Expands Collaboration with HepatoSys Systems Biology Network

  • Genedata extended its collaboration with the HepatoSys research network by three years. HepatoSys, an interdisciplinary initiative funded in 2003 by several German research centers, aims to understand the physiology and pathophysiology of the human liver cell using a systems biology approach.

    In the first funding period of HepatoSys, Genedata was tasked to develop and establish a computational platform to serve as the consortium's central data storage and analysis infrastructure. The platform—built on Genedata's Phylosopher® and Expressionist®—was successfully deployed and is now being used by the consortium.

    The centralized data storage infrastructure enables an integrative approach to the interpretation of systems biology modeling results in the context of experimental findings, including high-throughput transcriptomics, proteomics, and metabolomics data.

    Taking the collaboration to the next level, Genedata will now work on data analysis projects to interpret the huge amounts of molecular profiling data generated within the HepatoSys consortium.

    "After having built successfully on Genedata's track record in developing our scientific computing infrastructure, we see a tremendous opportunity in bringing together our academic expertise with Genedata's know-how to transfer systems biology applications to the pharmaceutical industry," remarks Jens Timmer, scientific spokesman for HepatoSys.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »